Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
TSN222 / Tyligand
NCT05842785: TSN222 in Subjects With Advanced Solid Tumors or Lymphomas	Recruiting	1/2	162	RoW	Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma, Phase II-solid tumors or lymphomas	Tyligand Bioscience (Shanghai) Limited	Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma	06/25	06/26